Hims & Hers Health

HIMS

Market cap $5B

Hims & Hers has sharply declined, losing nearly 40% YTD and two-thirds from last year's peak. Despite the selloff, I see compelling value in HIMS at its current, compressed valuation. Markets have penalized the stock for its expectation of slight adjusted EBITDA margin contraction in FY26, which is due to its expansion into new markets (Europe and Japan). The company's $1.15 billion acquisition of Eucalyptus (closing mid-2026) jumpstarts its international push, and lays the foundation for the company to scale to profitability overseas.

HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenc.

Hims & Hers announced its strategy around AI and how it fits into the company's platform. AI could enable more products and solutions for users outside of traditional prescriptions.

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at about $20 on Wednesday, down almost 39% so far this year.

LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Hims & Hers Health is evolving from a telehealth provider into a scalable, global consumer health platform with diversified growth drivers. The Novo Nordisk partnership validates HIMS' platform, but execution and regulatory risks in obesity treatments remain material to the thesis. International expansion, notably the Eucalyptus acquisition, and new service categories support robust revenue growth and platform monetization.

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.

American Express, KKR, and other financial stocks are trading at multi-year low valuations, and insider buying at KKR suggests the private credit panic may be overdone.